HRMY vs. AVDL, SUPN, AMRX, GPCR, TARO, PTGX, DVAX, CPRX, ZLAB, and SNDX
Should you be buying Harmony Biosciences stock or one of its competitors? The main competitors of Harmony Biosciences include Avadel Pharmaceuticals (AVDL), Supernus Pharmaceuticals (SUPN), Amneal Pharmaceuticals (AMRX), Structure Therapeutics (GPCR), Taro Pharmaceutical Industries (TARO), Protagonist Therapeutics (PTGX), Dynavax Technologies (DVAX), Catalyst Pharmaceuticals (CPRX), Zai Lab (ZLAB), and Syndax Pharmaceuticals (SNDX). These companies are all part of the "pharmaceutical preparations" industry.
Harmony Biosciences (NASDAQ:HRMY) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.
Harmony Biosciences currently has a consensus target price of $40.63, indicating a potential upside of 38.56%. Avadel Pharmaceuticals has a consensus target price of $22.57, indicating a potential upside of 26.73%. Given Harmony Biosciences' higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Avadel Pharmaceuticals.
Harmony Biosciences has a net margin of 22.16% compared to Avadel Pharmaceuticals' net margin of 0.00%. Harmony Biosciences' return on equity of 27.49% beat Avadel Pharmaceuticals' return on equity.
Harmony Biosciences has higher revenue and earnings than Avadel Pharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.
Harmony Biosciences has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
Avadel Pharmaceuticals received 287 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 65.01% of users gave Avadel Pharmaceuticals an outperform vote while only 59.70% of users gave Harmony Biosciences an outperform vote.
86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 30.8% of Harmony Biosciences shares are owned by insiders. Comparatively, 4.0% of Avadel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Harmony Biosciences had 2 more articles in the media than Avadel Pharmaceuticals. MarketBeat recorded 5 mentions for Harmony Biosciences and 3 mentions for Avadel Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.24 beat Avadel Pharmaceuticals' score of 0.45 indicating that Harmony Biosciences is being referred to more favorably in the media.
Summary
Harmony Biosciences beats Avadel Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Harmony Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for HRMY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harmony Biosciences Competitors List
Related Companies and Tools
